tysabri is reviewed to treat crohns associated press elan corp and biogen idec inc the makers of tysabri said u s regulators would review the drug for possible use by sufferers of the gastrointestinal ailment crohns disease the companies said two review committees of the food and drug administration would jointly consider on july whether to permit sale of tysabri to treat crohns which causes chronic but nonfatal inflammation of the intestines clinical trials of tysabri which last year was approved for use in the u s and european union to combat the most advanced cases of multiple sclerosis have indicated that the drug is effective in preventing inflammatory immune cells from penetrating the wall of the intestine limiting the damage they can cause 
